Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
162.00    -1.50 (-0.93%)
Bid:
159.00
Ask:
162.00
Spread: 3.00 (1.887%)
Market Cap: £1.39b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Joint venture with The Hain Celestial Group

8 Oct 2009 07:00

RNS Number : 4441A
Hutchison China Meditech Limited
08 October 2009
 



Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

Chi-Med announces joint venture with The Hain Celestial Group to develop natural and organic consumer products in Asia 

London: Thursday, 8 October 2009: Chi-Med, the majority owned subsidiary of Hutchison Whampoa Limited ("Hutchison Whampoa"), with pharmaceutical and healthcare operations primarily in China, today announced the signing of a joint venture agreement between its wholly-owned subsidiary, Hutchison Organic Holdings Limited, and The Hain Celestial Group, Inc. (NASDAQ: HAIN), a leading natural and organic products company ("Hain Celestial"). The joint venture will market and distribute infant and toddler feeding products co-branded under the Earth's Best[R] and Zhi Ling Tong brand names as well as selected Hain Celestial brands in China and other markets which can leverage upon the worldwide retail network for product distribution of the Hutchison Whampoa group. Under the terms of the joint venture agreement, each partner will own 50% of a newly created entity, Hutchison Hain Organic Holdings Limited, to conduct this marketing and distribution business.

"We have established a strong foundation for our brands in North America and Europe and look to deepen our franchise and widen our reach into China and to Asia," said Irwin D. Simon, President and Chief Executive Officer of Hain Celestial. "Our joint venture with an esteemed partner in Chi-Med and Hutchison Whampoa accelerates our entry with a partner whose values and product portfolio are entirely consistent with ours."

 

Christian Hogg, Chief Executive Officer of Chi-Med, said, "Tapping into Hain Celestial's know-how in natural and organic infant feeding is an important step forward in Chi-Med's strategy. The joint venture leverages Chi-Med's extensive China distribution network and significantly adds to our platform in infant nutrition, one of China's fastest growing categories. It also capitalises on the long-established relationships and international retail strengths of Hutchison Whampoa to grow Hain Celestial's portfolio of brands in the region, to our mutual benefit." 

Chi-Med has a strong position in pharmaceutical and healthcare products in China, including an extensive distribution network. With its highly respected Zhi Ling Tong brand, it also has a strong platform and rapidly growing sales in the Chinese infant nutrition supplements market. Hain Celestial is a leading natural and organic products company in North America and Europe, and Earth's Best[R] is one of the fastest growing established brands in infant feeding in the United States. Through its wholly owned A.S. Watson Group, Hutchison Whampoa is a major international retailer with over 8,400 retail shops in 34 markets. A.S. Watson has a strong presence in Asia with over 270 supermarkets and mega stores under the name PARKnSHOP and over 1,700 Watson's health and beauty stores. In Europe, it has over 1,600 luxury perfumery and cosmetics stores and over 4,700 health & beauty stores under brand names including Superdrug (UK), Marionnaud (France, Austria, Italy, Spain, Switzerland, and Portugal), Rossmann (Germany), Kruidvat, ICI Paris XL, and Trekpleister (Belgium and Netherlands).

Ends

Enquiries

For Chi-Med

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone: +44 (0) 20 7638 9571

+44 (0) 7973 611 888

+44 (0) 7967 566 919

For Hain Celestial 

Kekst and Company

David Lilly

Paige Gruman

Telephone: +1 212 521 4800

About Chi-Med 

Chi-Med (AIM: HCM) is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients. Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited. For more information, visit www.chi-med.com.

About The Hain Celestial Group

The Hain Celestial Group (NASDAQ: HAIN), headquartered in MelvilleNY, is a leading natural and organic company in North America and Europe. Hain Celestial reported turnover of approximately USD 1.06 billion for the year ended 31 December 2008. Hain Celestial participates in almost all natural food categories with well-known brands that include Celestial Seasonings[R], Terra[R], Garden of Eatin'[R], Health Valley[R], WestSoy[R], Earth's Best[R], Arrowhead Mills[R], MaraNatha[R], SunSpire[R], DeBoles[R], Hain Pure Foods[R], Hollywood[R], Spectrum Naturals[R], Spectrum Essentials[R], Walnut Acres Organic[R], Imagine[R], Rice Dream[R], Soy Dream[R], Rosetto[R], Ethnic Gourmet[R], Yves Veggie Cuisine[R], Granose[R], Realeat[R], Linda McCartney[R], Daily Bread[TM], Lima[R], Grains Noirs[R], Natumi[R], JASON[R], Zia[R] Natural Skincare, Avalon Organics[R], Alba Botanica[R], Queen Helene[R], Tushies[R] and TenderCare[R]. Hain Celestial has been providing "A Healthy Way of Life[TM]" since 1993. For more information, visit www.hain-celestial.com.

About Hutchison Whampoa Limited ("Hutchison Whampoa")

Hutchison Whampoa is a leading international corporation committed to innovation and technology with businesses spanning the globe. Its diverse array of holdings range from some of the world's biggest port operators and retailers to property development and infrastructure to the most technologically-advanced and marketing-savvy telecommunications operators. Hutchison Whampoa reported turnover of approximately HKD 348 billion (USD 45 billion) for the year ended 31 December 2008. With operations in 54 countries and over 220,000 employees worldwide, Hutchison Whampoa has five core businesses - ports and related services; property and hotels; retail; energy and infrastructure, finance and investments, and others; and telecommunications. Hutchison Whampoa is among the largest companies listed on the main board of the Hong Kong Stock Exchange. Flagship companies include Hutchison Port Holdings, Hutchison Whampoa Properties, A S Watson, Cheung Kong Infrastructure and Hutchison Telecom. For more information, visit www.hutchison-whampoa.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
JVEFSISIASUSEIS
Date   Source Headline
30th Jun 20269:30 amRNSHUTCHMED to Announce 2026 Half-Year Results
29th Jun 20269:30 amRNSAnnouncement on blocklisting six monthly return
25th Jun 20267:00 amRNS-RHUTCHMED Highlights Phase II Data at ESMO
12th Jun 20267:00 amRNS-RHUTCHMED Highlights Sovleplenib Phase III Data
5th Jun 20269:30 amRNSBlock Admission Application
22nd May 20267:00 amRNS-RHUTCHMED Highlights Data to be Presented at ASCO
21st May 202611:00 amRNS-RNMPA approval for ELUNATE with TYVYT
12th May 202612:45 pmRNSAnnouncement on Results of Annual General Meeting
30th Apr 20269:30 amRNSTotal Voting Rights
29th Apr 202611:00 amRNS-RHUTCHMED Announces NDA Acceptance in China
9th Apr 20269:30 amRNS2025 Annual Report and Notice of AGM
9th Apr 20267:00 amRNS-RData to be Presented at AACR Annual Meeting 2026
23rd Mar 20267:00 amRNS-RHUTCHMED Initiates Phase III Trial of HMPL-760
16th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
16th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
11th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
11th Mar 20268:30 amRNSVesting of awards under Long Term Incentive Plan
9th Mar 20269:30 amRNSUpdate on Licensed Oncology Product in China
6th Mar 20268:30 amRNSDirectorate change
5th Mar 20261:00 pmRNS-RPublication of Form 20-F
5th Mar 202611:00 amRNS2025 Full Year Results and Business Updates
4th Mar 20268:30 amRNS-RHUTCHMED Initiates Global Trial of ATTC Candidate
6th Feb 20268:30 amRNSHUTCHMED to Announce 2025 Final Results
14th Jan 20267:00 amRNS-RPublication of Phase III Results in The Lancet
7th Jan 20267:00 amRNS-RPositive Topline Results of Phase III Trial
5th Jan 20267:00 amRNS-RSurufatinib + Camrelizumab PDAC Phase 3 initiation
31st Dec 20257:00 amRNSTotal Voting Rights
31st Dec 20257:00 amRNSTotal Voting Rights
30th Dec 202510:00 amRNS-RChina NDA Acceptance-Savolitinib in Gastric Cancer
30th Dec 202510:00 amRNS-RChina NDA Acceptance-Savolitinib in Gastric Cancer
29th Dec 20258:30 amRNSBlocklisting Six Monthly Return
29th Dec 20258:30 amRNS-RNDA Acceptance in China for Fanregratinib
29th Dec 20258:30 amRNS-RNDA Acceptance in China for Fanregratinib
29th Dec 20258:30 amRNSBlocklisting Six Monthly Return
17th Dec 20257:00 amRNS-RHUTCHMED Initiates Development of ATTC Candidate
8th Dec 20257:00 amRNSExpanded NRDL Coverage + CIDL Inclusion in China
28th Nov 20258:30 amRNSTotal Voting Rights
27th Nov 20257:00 amRNS-RHUTCHMED Highlights Data at ESMO and ASH
5th Nov 20257:00 amRNS-REnrollment Complete in SAFFRON Global Phase III
3rd Nov 20257:00 amRNS-RUpdates from R&D Event
23rd Oct 20257:00 amRNS-RHUTCHMED Presents Data at AACR NCI EORTC
21st Oct 20259:30 amRNSVesting of awards under Long Term Incentive Plan
14th Oct 20259:30 amRNSAppointment of Independent Non-executive Director
13th Oct 20257:05 amRNS-RData to be Presented at the 2025 ESMO Congress
2nd Oct 20257:00 amRNS-RHUTCHMED Highlights Data to be Presented at ESMO
30th Sep 20259:30 amRNSTotal Voting Rights
12th Sep 20257:00 amRNS-RHUTCHMED to Present R&D Updates on October 31 2025
5th Sep 20257:00 amRNS-RHUTCHMED Highlights Data to be Presented at CSCO
26th Aug 20257:00 amRNSDirectorate Change
20th Aug 20257:00 amRNS-RHUTCHMED Completes Enrollment of Phase III Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.